Povsic Thomas J
Duke Clinical Research Institute and Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, 27708, USA.
Curr Cardiol Rep. 2016 Feb;18(2):17. doi: 10.1007/s11886-015-0693-6.
Improvements in the care of patients with ischemic cardiovascular disease have led to improved survival but also a burgeoning population of patients with advanced ischemic heart disease. Cell therapies offer a novel approach toward cardiac "rejuvenation" via stimulation of new blood vessel growth, enhancing tissue perfusion, and via preservation or even regeneration of myocardial tissue, leading to improvements in cardiac performance after myocardial infarction and in patients with advanced heart failure. Here, we summarize and offer some thoughts on the state of the field of cell therapy for ischemic heart disease, targeting three separate conditions that have been the subject of significant clinical research: enhancing left ventricular recovery after MI, improving outcomes and symptoms in patients with congestive heart failure (CHF), and treatment of patients with refractory angina, despite maximal medical therapy.
缺血性心血管疾病患者护理的改善提高了生存率,但也导致了晚期缺血性心脏病患者数量的不断增加。细胞疗法通过刺激新血管生长、增强组织灌注以及保存甚至再生心肌组织,为心脏“年轻化”提供了一种新方法,从而改善心肌梗死后和晚期心力衰竭患者的心脏功能。在此,我们总结并对缺血性心脏病细胞治疗领域的现状提出一些看法,针对已成为大量临床研究主题的三种不同情况:提高心肌梗死后左心室恢复能力、改善充血性心力衰竭(CHF)患者的预后和症状,以及治疗尽管接受了最大程度药物治疗仍患有顽固性心绞痛的患者。